标题
Resistance to proteasome inhibitors and other targeted therapies in myeloma
作者
关键词
-
出版物
BRITISH JOURNAL OF HAEMATOLOGY
Volume 182, Issue 1, Pages 11-28
出版商
Wiley
发表日期
2018-04-20
DOI
10.1111/bjh.15210
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Safety of ixazomib for the treatment of multiple myeloma
- (2017) Antoine Bonnet et al. Expert Opinion On Drug Safety
- Carfilzomib resistance due to ABCB1/MDR1 overexpression is overcome by nelfinavir and lopinavir in multiple myeloma
- (2017) A Besse et al. LEUKEMIA
- Expression and release of glucose-regulated protein-78 (GRP78) in multiple myeloma
- (2017) Normann Steiner et al. Oncotarget
- Molecular signaling in multiple myeloma: association of RAS/RAF mutations and MEK/ERK pathway activation
- (2017) J Xu et al. Oncogenesis
- Phase 1 study of marizomib in relapsed or relapsed and refractory multiple myeloma: NPI-0052-101 Part 1
- (2016) P. G. Richardson et al. BLOOD
- CD38 expression and complement inhibitors affect response and resistance to daratumumab therapy in myeloma
- (2016) Inger S. Nijhof et al. BLOOD
- Targeted sequencing of refractory myeloma reveals a high incidence of mutations in CRBN and Ras pathway genes
- (2016) K. M. Kortum et al. BLOOD
- Tight Junction Protein 1 Modulates Proteasome Capacity and Proteasome Inhibitor Sensitivity in Multiple Myeloma via EGFR/JAK1/STAT3 Signaling
- (2016) Xing-Ding Zhang et al. CANCER CELL
- A GRP78-Directed Monoclonal Antibody Recaptures Response in Refractory Multiple Myeloma with Extramedullary Involvement
- (2016) L. Rasche et al. CLINICAL CANCER RESEARCH
- Vemurafenib in combination with cobimetinib in relapsed and refractory extramedullary multiple myeloma harboring the BRAF V600E mutation
- (2016) Ulrich J.M. Mey et al. HEMATOLOGICAL ONCOLOGY
- Monoclonal antibodies targeting CD38 in hematological malignancies and beyond
- (2016) Niels W. C. J. van de Donk et al. IMMUNOLOGICAL REVIEWS
- Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial
- (2016) Sagar Lonial et al. LANCET
- Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study
- (2016) Meletios A Dimopoulos et al. LANCET ONCOLOGY
- Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma
- (2016) Philippe Moreau et al. NEW ENGLAND JOURNAL OF MEDICINE
- Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma
- (2016) Meletios A. Dimopoulos et al. NEW ENGLAND JOURNAL OF MEDICINE
- Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma
- (2016) Antonio Palumbo et al. NEW ENGLAND JOURNAL OF MEDICINE
- Role of micro-RNAs in drug resistance of multiple myeloma
- (2016) Jahangir Abdi et al. Oncotarget
- Microenvironment drug resistance in multiple myeloma: emerging new players
- (2016) Lucia Di Marzo et al. Oncotarget
- Identification of markers that functionally define a quiescent multiple myeloma cell sub-population surviving bortezomib treatment
- (2015) Alfred Adomako et al. BMC CANCER
- The Nuclear Factor (Erythroid-derived 2)-like 2 and Proteasome Maturation Protein Axis Mediate Bortezomib Resistance in Multiple Myeloma
- (2015) Bingzong Li et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Multiple myeloma
- (2015) Christoph Röllig et al. LANCET
- Upregulation of CD38 expression on multiple myeloma cells by all-trans retinoic acid improves the efficacy of daratumumab
- (2015) I S Nijhof et al. LEUKEMIA
- Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma
- (2015) Sagar Lonial et al. NEW ENGLAND JOURNAL OF MEDICINE
- Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma
- (2015) A. Keith Stewart et al. NEW ENGLAND JOURNAL OF MEDICINE
- Mechanism of Action of Bortezomib and the New Proteasome Inhibitors on Myeloma Cells and the Bone Microenvironment: Impact on Myeloma-Induced Alterations of Bone Remodeling
- (2015) Fabrizio Accardi et al. Biomed Research International
- The small heat shock protein B8 (HSPB8) confers resistance to bortezomib by promoting autophagic removal of misfolded proteins in multiple myeloma cells
- (2015) Mohamed-Amine Hamouda et al. Oncotarget
- Heat shock proteins in multiple myeloma
- (2015) Lei Zhang et al. Oncotarget
- Structural and Functional Insights to Ubiquitin-Like Protein Conjugation
- (2014) Frederick C. Streich et al. Annual Review of Biophysics
- Bone marrow stromal cell-derived exosomes as communicators in drug resistance in multiple myeloma cells
- (2014) J. Wang et al. BLOOD
- The novel AKT inhibitor afuresertib shows favorable safety, pharmacokinetics, and clinical activity in multiple myeloma
- (2014) A. Spencer et al. BLOOD
- Identification of cereblon-binding proteins and relationship with response and survival after IMiDs in multiple myeloma
- (2014) Y. X. Zhu et al. BLOOD
- A HGF/cMET Autocrine Loop Is Operative in Multiple Myeloma Bone Marrow Endothelial Cells and May Represent a Novel Therapeutic Target
- (2014) A. Ferrucci et al. CLINICAL CANCER RESEARCH
- Proteasome inhibitors - molecular basis and current perspectives in multiple myeloma
- (2014) Lenka Kubiczkova et al. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
- Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial
- (2014) Jesús F San-Miguel et al. LANCET ONCOLOGY
- What do drug transporters really do?
- (2014) Sanjay K. Nigam NATURE REVIEWS DRUG DISCOVERY
- Identification of an ABCB1 (P-glycoprotein)-positive carfilzomib-resistant myeloma subpopulation by the pluripotent stem cell fluorescent dye CDy1
- (2013) Teresa S. Hawley et al. AMERICAN JOURNAL OF HEMATOLOGY
- High expression of cereblon (CRBN) is associated with improved clinical response in patients with multiple myeloma treated with lenalidomide and dexamethasone
- (2013) Daniel Heintel et al. BRITISH JOURNAL OF HAEMATOLOGY
- A phase 2 multicentre study of siltuximab, an anti-interleukin-6 monoclonal antibody, in patients with relapsed or refractory multiple myeloma
- (2013) Peter M. Voorhees et al. BRITISH JOURNAL OF HAEMATOLOGY
- Xbp1s-Negative Tumor B Cells and Pre-Plasmablasts Mediate Therapeutic Proteasome Inhibitor Resistance in Multiple Myeloma
- (2013) Chungyee Leung-Hagesteijn et al. CANCER CELL
- Novel Targeting of Phospho-cMET Overcomes Drug Resistance and Induces Antitumor Activity in Multiple Myeloma
- (2013) M. Moschetta et al. CLINICAL CANCER RESEARCH
- Do baseline Cereblon gene expression and IL-6 receptor expression determine the response to thalidomide-dexamethasone treatment in Multiple myeloma patients?
- (2013) Ahmed M. L. Bedewy et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial
- (2013) Jesus San Miguel et al. LANCET ONCOLOGY
- Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients
- (2013) S K Kumar et al. LEUKEMIA
- Evidence of a role for CD44 and cell adhesion in mediating resistance to lenalidomide in multiple myeloma: therapeutic implications
- (2013) C C Bjorklund et al. LEUKEMIA
- The clinical significance of cereblon expression in multiple myeloma
- (2013) Steven R. Schuster et al. LEUKEMIA RESEARCH
- Endoplasmic Reticulum Stress and the Unfolded Protein Response: Targeting the Achilles Heel of Multiple Myeloma
- (2013) L. Vincenz et al. MOLECULAR CANCER THERAPEUTICS
- Profiling Bortezomib Resistance Identifies Secondary Therapies in a Mouse Myeloma Model
- (2013) H. A. F. Stessman et al. MOLECULAR CANCER THERAPEUTICS
- A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma
- (2012) D. S. Siegel et al. BLOOD
- Sequence analysis of -subunit genes of the 20S proteasome in patients with relapsed multiple myeloma treated with bortezomib or dexamethasone
- (2012) D. I. Lichter et al. BLOOD
- Targeting the insulin-like growth factor-1 receptor to overcome bortezomib resistance in preclinical models of multiple myeloma
- (2012) D. J. Kuhn et al. BLOOD
- Bone Marrow Microenvironment in Multiple Myeloma Progression
- (2012) S. Manier et al. JOURNAL OF BIOMEDICINE AND BIOTECHNOLOGY
- Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide
- (2012) A Lopez-Girona et al. LEUKEMIA
- Integrin 7-mediated regulation of multiple myeloma cell adhesion, migration, and invasion
- (2011) P. Neri et al. BLOOD
- A phase 1, multicenter, open-label, dose escalation study of elotuzumab in patients with advanced multiple myeloma
- (2011) J. A. Zonder et al. BLOOD
- Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide
- (2011) Y. X. Zhu et al. BLOOD
- Treatment-Induced Oxidative Stress and Cellular Antioxidant Capacity Determine Response to Bortezomib in Mantle Cell Lymphoma
- (2011) M. A. Weniger et al. CLINICAL CANCER RESEARCH
- Suppressing miRNA-15a/-16 expression by interleukin-6 enhances drug-resistance in myeloma cells
- (2011) Mu Hao et al. Journal of Hematology & Oncology
- Phase I study of the anti insulin-like growth factor 1 receptor (IGF-1R) monoclonal antibody, AVE1642, as single agent and in combination with bortezomib in patients with relapsed multiple myeloma
- (2011) P Moreau et al. LEUKEMIA
- Monoclonal antibody-based therapy as a new treatment strategy in multiple myeloma
- (2011) N W C J van de Donk et al. LEUKEMIA
- Bortezomib resistance in a myeloma cell line is associated to PSMβ5 overexpression and polyploidy
- (2011) Patricia Balsas et al. LEUKEMIA RESEARCH
- Initial genome sequencing and analysis of multiple myeloma
- (2011) Michael A. Chapman et al. NATURE
- The Hsp90 inhibitor IPI-504 overcomes bortezomib resistance in mantle cell lymphoma in vitro and in vivo by down-regulation of the prosurvival ER chaperone BiP/Grp78
- (2010) G. Roue et al. BLOOD
- A novel orally active proteasome inhibitor ONX 0912 triggers in vitro and in vivo cytotoxicity in multiple myeloma
- (2010) D. Chauhan et al. BLOOD
- Bortezomib resistance in mantle cell lymphoma is associated with plasmacytic differentiation
- (2010) P. Perez-Galan et al. BLOOD
- Bortezomib-resistant myeloma cell lines: a role for mutated PSMB5 in preventing the accumulation of unfolded proteins and fatal ER stress
- (2010) M Ri et al. LEUKEMIA
- Identification of a Primary Target of Thalidomide Teratogenicity
- (2010) T. Ito et al. SCIENCE
- Bortezomib induces canonical nuclear factor- B activation in multiple myeloma cells
- (2009) T. Hideshima et al. BLOOD
- Molecular basis of bortezomib resistance: proteasome subunit 5 (PSMB5) gene mutation and overexpression of PSMB5 protein
- (2008) R. Oerlemans et al. BLOOD
- CS1, a Potential New Therapeutic Antibody Target for the Treatment of Multiple Myeloma
- (2008) E. D. Hsi et al. CLINICAL CANCER RESEARCH
- Overexpression of the PSMB5 gene contributes to bortezomib resistance in T-lymphoblastic lymphoma/leukemia cells derived from Jurkat line
- (2008) Shuqing Lü et al. EXPERIMENTAL HEMATOLOGY
- Point Mutation of the Proteasome 5 Subunit Gene Is an Important Mechanism of Bortezomib Resistance in Bortezomib-Selected Variants of Jurkat T Cell Lymphoblastic Lymphoma/Leukemia Line
- (2008) S. Lu et al. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
- Bone marrow microenvironment and the identification of new targets for myeloma therapy
- (2008) K Podar et al. LEUKEMIA
- Bortezomib-Resistant Nuclear Factor- B Activity in Multiple Myeloma Cells
- (2008) S. Markovina et al. MOLECULAR CANCER RESEARCH
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started